Recently, we demonstrated that sustained activation of TFEB is the main driver of renal tumorigenesis in a mouse model of BHD syndrome, which is caused by FLCN mutations, prompting research into strategies to counteract TFEB activation [9]. The gene discussed is FLCN; the disease is Birt-Hogg-Dubé syndrome.